Lovastatin may prevent development of cardiovascular disease (CVD) in CKD patients, according to study findings published in the American Journal of Kidney Diseases (2009; published online ahead of print).
The study included 5,608 men and 997 women without CVD randomized to receive either lovastatin or placebo.
After an average follow-up of 5.3 years, lovastatin recipients had a 69% decreased risk of a CVD event compared with the placebo arm, after adjusting for potential confounders.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.
